CIPDB › China Industry › Chemicals › Pharmaceutical Intermediate
Fitness and Weight Loss Retatrutide Raw Powder Retatrutide1
Pharmaceutical IntermediateRetatrutidePeptide Retatrutide
Xi'an Qiushi Co., Ltd.
Preview:
Product Description Fitness and Weight Loss Retatrutide Raw Powder RetatrutideProduct DescriptionProduct DetailsProduct NameRetatrutideAppearanceWhite PowderAssay99%CAS2381089-83-2MW4731.33Retatrutide is a triple agonist peptide that can activate glucagon receptor (GCGR), glucose dependent insulinotropic polypeptide receptor (GIPR), and glucagon like peptide-1 receptor (GLP-1R).Retatrutide (LY3437943) acetate is a triple agonist peptide of glucagon receptor (GCGR), glucose dependent insulinotropic polypeptide receptor (GIPR), and glucagon like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R, with EC50 values of 5.79, 0.0643, and 0.775 nM, respectively. Retatrutide acetate exhibits activity against GCGR, GIPR, and GLP-1R in mice, with EC50 values of 2.32, 0.191, and 0.794 nM, respectively. Retatrutide (LY3437943) acetate participates in GCGR in vivo and can improve glucose tolerance in ipGTT through GIP or GLP-1 receptors. Retatrutide acetate activates glucagon receptors, leading to significant weight loss and increased energy expenditure. Retatrutide acetate can be used for research on obesity. Application&Function Retatrutide (LY3437943) is a triple agonist peptide that can simultaneously activate glucagon receptor (GCGR), glucose dependent insulinotropic polypeptide receptor (GIPR), and glucagon like peptide-1 receptor (GLP-1R).The main pharmacological effects of Retatrutide are as follows:Retarutide acetate exhibited activity at EC50 values of 5.79, 0.0643, and 0.775 nM, respectively, by inhibiting human GCGR, GIPR, and GLP-1R.In a mouse model, Retarutide acetate exhibited similar activity with EC50 values of 2.32, 0.191, and 0.794 nM for GCGR, GIPR, and GLP-1R, respectively.Through activation of glucagon receptors, Retarutide acetate can lead to significant weight loss and increased energy expenditure, making it potentially valuable for obesity research.In vivo, Retatrutide participates in GCGR and can improve glucose tolerance in ipGTT through GIP or GLP-1 receptors.Clinical studies have shown that Retatrutide can help obese patients lose an average of 24% of their weight within 48 weeks, which is one of the largest weight loss effects seen so far.In addition, Retatrutide has shown effects in lowering blood pressure and improving blood glucose control. In patients with pre diabetes, nearly three quarters of patients have reached normal blood sugar levels by 48 weeks.Specification About US
Purchasing Agent
Note: Send your message to supplier or manufacturer.
Welcome to our Professional and comprehensive procurement services...